Daniel E. Epner, MD; H. Phillip Koeffler, MD
While cytogenetics has been central to the study of chronic myelogenous leukemia since the discovery of the Philadelphia chromosome (Ph1) in 1960 (1, 2), the major thrust of research in recent years has been the clarification of the pathogenesis of the disease at the molecular level. Of the many variants of the Ph1 which are known to exist, all share one crucial molecular event. Abelson proto-oncogene, or ABL, is translocated from the long arm of chromosome 9 to a position adjacent to the breakpoint cluster region (BCR) gene on chromosome 22 (Figure 1, top).
The ABL gene is the normal
Epner DE, Koeffler HP. Molecular Genetic Advances in Chronic Myelogenous Leukemia. Ann Intern Med. ;113:3–6. doi: 10.7326/0003-4819-113-1-3
Download citation file:
Published: Ann Intern Med. 1990;113(1):3-6.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use